French first lady in new role as AIDS ambassador AFP - Set up in 2002, the fund has invested more than eight billion dollars to support national AIDS treatment programmes, out of the 14 billion dollars spent to ...
[CITATION] The analysis of randomized and non-randomized AIDS treatment trials using a new approach to causal … JM Robins - Health Service Research Methodology: A Focus on AIDS, 1989 - NCHSR, US Public Health Service
SUNDAY, Aug. 13 (HealthDay News) -- Updated treatment guidelines for adult HIV patients that reflect new developments in antiretroviral therapy have been issued by the International AIDS Society-USA Panel.
The revised recommendations, published in the Aug. 16 issue of the Journal of the American Medical Association, were to be presented Sunday at the International AIDS Conference in Toronto.
The guidelines focus on four areas: when to start antiretroviral therapy; what to start; when to change; and what to change.
The 16-member panel continues to recommend the start of antiretroviral therapy in all HIV-infected people with symptoms and in those with no symptoms after the CD4 cell count falls below 350/uL and before it declines to 200/uL.
Since the last edition of the guidelines, findings from clinical trials and cohort studies have led to refinements in the choice of initial antiretroviral regimen, the panel members noted.
"The recommended initial regimen remains a combination of 2 nucleoside (or nucleotide) reverse transcriptase inhibitors (nRTIs) with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a protease inhibitor (PI) boosted with low-dose ritonavir," the panel wrote.
Given the high degree of compatibility of the recommended components of these regimens in treatment-naive persons with drug susceptible virus, the choice of regimen centers on acceptability; predicted tolerance; pill burden; comorbid conditions; short-term, mid-term, and long-term adverse event profiles; and successful alternatives should the initial regimen fail and drug resistance emerge. The successful outcome of several 'switch studies' suggest that the initial choice of regimen does not preclude safely changing drugs once viral suppression is achieved," the panel said.
The panel added that adherence to antiretroviral therapy in the short- and long-term is vital for treatment success and must be continually reinforced with patients.
Antiretroviral therapy should be changed when toxicity or intolerance makes it necessary or when the treatment fails.
The panel also wrote that the virologic target for patients with treatment failure is now a plasma HIV-1 RNA level below 50 copies/mL. This goal is achievable in many patients.
Once antiretroviral therapy is started, plasma HIV-1 RNA level should be checked every four to eight weeks until it's below the limits of detection. After that, HIV-1 RNA level should be checked three to four times a year.
"Given the rapid evolution of knowledge, clinicians are challenged to stay abreast of new information that can affect practice. Therapeutic choices rooted in the pathogenesis of HIV disease and individualization of therapy to maximize benefit are the principles that remain constant in a rapidly changing environment," the panel wrote.
More information
The U.S. National Institute of Allergy and Infectious Diseases has more about HIV treatment.
Comment by Julie Davids